J&J JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting label expansion ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his ...

Medtronic remains a dependable dividend aristocrat, but its long-term total shareholder returns lag significantly behind ...

Brian Gutekunst already created a wide receiver headache by signing Mecole Hardman before drafting Matthew Golden and Savion ...

If you’re looking for a lesser-known player for whom to root at this week’s U.S. Open, Chase Johnson isn’t a bad option.

There’s no sign that anyone in Springfield or Chicago City Hall is willing to make the hard choices real leaders are supposed to make.

Consider the drug Procrit, J&J’s synthetic brand of the protein erythropoietin (EPO), which is designed to increase the volume of oxygen-carrying red blood ... Johnson & Johnson has also played ...

“For too long, Johnson & Johnson has used tying arrangements and ... all proposals past legal/procurement for anti-competitive red flags. Price gouging on the “reprocessable” model Track ...

In “No More Tears: The Dark Secrets of Johnson & Johnson,” investigative reporter ... which stimulates the bone marrow to produce red blood cells but also turned out to stimulate tumor growth ...

FILE - The Johnson & Johnson logo appears above a trading post ... to dismiss the Chapter 11 bankruptcy petition filed by Red River Talc, a subsidiary of J&J, but to allow the parties to either ...